StockDriftsStockDriftsTop 6 Atlas Venture Life Science Advisors LLC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | 37.05% | 2.85M | $326.5M | -37.80%(-1.73M) | $61.12(+92.08%) | 2026-06-30 | |
| DYN | Dyne Therapeutics, Inc. | 17.14% | 6.80M | $151.0M | -25.52%(-2.33M) | $14.26(+80.22%) | 2026-06-30 | |
| SION | Sionna Therapeutics, Inc. | 14.95% | 3.00M | $131.8M | +0.00%(+0) | $10.46(-38.24%) | 2026-06-30 | |
| IRON | Disc Medicine, Inc. | 12.56% | 1.51M | $110.7M | +0.00%(+0) | $36.24(+117.56%) | 2026-06-30 | |
| QTTB | Q32 Bio, Inc. | 3.93% | 2.72M | $34.6M | +29.87%(+625.00K) | $12.92(+17.28%) | 2026-06-30 | |
| KRRO | Korro Bio, Inc. | 1.44% | 962.9K | $12.7M | -15.32%(-174.26K) | $33.67(-60.55%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (18 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | +34.71% | +144.47% | — | — | +111.15% |
| Top 20 Holdings Unweighted | +57.68% | +292.05% | — | — | +319.22% |
Atlas Venture Life Science Advisors LLC reports $881.29M in US-listed equity holdings across 7 positions in its most recent 13F filing. Its largest disclosed positions are KYMR (37.0%), DYN (17.1%) and SION (14.9%). The top 20 holdings account for 87.07% of reported assets. Its disclosed equity book has returned +144.47% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Atlas Venture Life Science Advisors LLC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Atlas Venture Life Science Advisors LLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1917529). View Atlas Venture Life Science Advisors LLC’s 13F filings on SEC